Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has announced it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss results and provide a corporate update. Domestic callers can dial 1-800-717-1738, while international callers should use 1-646-307-1865 to participate.
Celcuity (Nasdaq: CELC), una società biotecnologica in fase clinica focalizzata su terapie oncologiche mirate, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato giovedì 14 novembre 2024. L'azienda ospiterà una webconferenza e una chiamata conferenza alle 16:30 ora orientale dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. I chiamanti nazionali possono comporre il numero 1-800-717-1738, mentre i chiamanti internazionali dovrebbero utilizzare il numero 1-646-307-1865 per partecipare.
Celcuity (Nasdaq: CELC), una compañía de biotecnología en etapa clínica enfocada en terapias de oncología dirigidas, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el jueves 14 de noviembre de 2024. La compañía llevará a cabo una transmisión web y una llamada de conferencia a las 4:30 p.m. hora del Este el mismo día para discutir los resultados y brindar una actualización corporativa. Los llamantes nacionales pueden marcar el 1-800-717-1738, mientras que los llamantes internacionales deben usar el 1-646-307-1865 para participar.
셀큐이티(Celcuity, Nasdaq: CELC)는 타겟 항암 치료에 초점을 맞춘 임상 단계의 생명공학 회사로, 2024년 3분기 재무보고서를 2024년 11월 14일 목요일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 기업 업데이트를 제공하기 위해 웹 세미나와 컨퍼런스 콜을 개최할 것입니다. 국내 발신자는 1-800-717-1738로 전화할 수 있으며, 해외 발신자는 1-646-307-1865를 사용해야 참여할 수 있습니다.
Celcuity (Nasdaq: CELC), une entreprise de biotechnologie en phase clinique axée sur les thérapies oncologiques ciblées, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture des marchés le jeudi 14 novembre 2024. L'entreprise organisera une webconférence et une conférence téléphonique à 16h30, heure de l'Est, le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise. Les appelants nationaux peuvent composer le 1-800-717-1738, tandis que les appelants internationaux doivent utiliser le 1-646-307-1865 pour participer.
Celcuity (Nasdaq: CELC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Onkologietherapien konzentriert, hat angekündigt, dass die Finanzergebnisse für das dritte Quartal 2024 nach dem Marktabschluss am Donnerstag, dem 14. November 2024, veröffentlicht werden. Das Unternehmen wird am gleichen Tag um 16:30 Uhr Eastern Time eine Webkonferenz und eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Einheimische Anrufer können die Nummer 1-800-717-1738 wählen, während internationale Anrufer die Nummer 1-646-307-1865 verwenden sollten, um teilzunehmen.
- None.
- None.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1688854&tp_key=0b14db1255. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Westwicke
Maria Yonkoski, maria.yonkoski@westwicke.com
(203) 682-7167
FAQ
When will Celcuity (CELC) release Q3 2024 earnings?
How can investors join Celcuity's (CELC) Q3 2024 earnings call?
Will there be a replay available for Celcuity's (CELC) Q3 2024 earnings call?
